Aguiar M, Marçal N, Mendes AC, Bugalho de Almeida A. Infliximab for treating sarcoidosis patients, Portuguese experience. Rev Port Pneumol. 2011;17:85–93. https://doi.org/10.1016/S0873-2159(11)70020-4.

Article  PubMed  Google Scholar 

Ahmed R, Dulay MS, Liu A, et al. Comparing outcomes of an early versus late diagnosis of cardiac sarcoidosis following a baseline presentation of high-grade atrioventricular block. Curr Probl Cardiol. 2024;49. https://doi.org/10.1016/J.CPCARDIOL.2024.102577.

Alqalyoobi S, Liao SY, Qureshi W, Obi ON. National temporal trends in hospitalization and inpatient mortality in patients with Pulmonary Sarcoidosis in the United States between 2007 and 2018. Chest. 2022;161:152–68. https://doi.org/10.1016/J.CHEST.2021.07.2166.

Article  PubMed  Google Scholar 

Ang QX, TMC, TJY & TJ. Abstract 15054: impact of sarcoidosis-related admission in patients with heart failure: a nationwide readmissions database analysis. Circulation. 2023;148. https://doi.org/10.1161/circ.148.suppl_1.15054

Bae K-N, Shin K, Kim H-S, et al. Scar sarcoidosis: a Retrospective Investigation into its Peculiar Clinicopathologic Presentation. Ann Dermatol. 2022;34:28–33. https://doi.org/10.5021/ad.2022.34.1.28.

Article  PubMed  PubMed Central  Google Scholar 

Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128:1062–7. https://doi.org/10.1378/CHEST.128.2.1062.

Article  PubMed  Google Scholar 

Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802. https://doi.org/10.1164/RCCM.200603-402OC.

Article  PubMed  Google Scholar 

Belperio JA, Shaikh F, Abtin FG, et al. Diagnosis and treatment of pulmonary sarcoidosis: a review. JAMA. 2022;327:856–67. https://doi.org/10.1001/jama.2022.1570.

Article  PubMed  Google Scholar 

Bueno-Beti C, Lim CX, Protonotarios A, et al. An mTORC1-Dependent mouse model for Cardiac Sarcoidosis. J Am Heart Assoc. 2023;12. https://doi.org/10.1161/JAHA.123.030478.

Cao Y, Afzal MZ, Gutmann EJ, Shirai K. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors. Melanoma Res. 2024;34:70–5. https://doi.org/10.1097/CMR.0000000000000925.

Article  PubMed  Google Scholar 

Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol. 2017;76:1–9. https://doi.org/10.1016/J.JAAD.2016.01.062.

Article  PubMed  Google Scholar 

Caplan A, Rosenbach M, Imadojemu S. Cutaneous Sarcoidosis. Semin Respir Crit Care Med. 2020;41:689–99. https://doi.org/10.1055/s-0040-1713130.

Article  PubMed  Google Scholar 

Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82:612–21. https://doi.org/10.1016/j.jaad.2019.05.098.

Article  PubMed  Google Scholar 

Facchinetti F, Gnetti L, Balestra V, et al. Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib. Invest New Drugs. 2019;37:360–3. https://doi.org/10.1007/s10637-018-0652-3.

Article  PubMed  Google Scholar 

Fidler LM, Gershon A, Fisher JH, et al. Hospitalizations in Sarcoidosis: a cohort study of a Universal Healthcare Population. Ann Am Thorac Soc. 2021;18:1786–94. https://doi.org/10.1513/ANNALSATS.202009-1134OC.

Article  PubMed  Google Scholar 

Friedman MA, Le B, Stevens J, et al. Tofacitinib as a steroid-sparing therapy in Pulmonary Sarcoidosis, an open-label prospective proof-of-Concept Study. Lung. 2021;199:147–53. https://doi.org/10.1007/S00408-021-00436-8.

Article  PubMed  PubMed Central  Google Scholar 

Fritz D, Ferwerda B, Van De Brouwer MC. Whole genome sequencing identifies variants associated with sarcoidosis in a family with a high prevalence of sarcoidosis. https://doi.org/10.1007/s10067-021-05684-w/Published

Gerke AK, Yang M, Tang F, et al. Increased hospitalizations among sarcoidosis patients from 1998 to 2008: a population-based cohort study. BMC Pulm Med. 2012;12. https://doi.org/10.1186/1471-2466-12-19.

Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. In: StatPearls; 2023.

Google Scholar 

Gleue CA, Shah K, Wentworth A, Bridges A. Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor. J Cutan Pathol. 2021;48:425–8. https://doi.org/10.1111/cup.13911.

Article  PubMed  Google Scholar 

Gosselin J, Roy-Hewitson C, Bullis SSM, et al. Neurosarcoidosis: phenotypes, Approach to diagnosis and treatment. Curr Rheumatol Rep. 2022;24:371–82. https://doi.org/10.1007/s11926-022-01089-z.

Article  PubMed  Google Scholar 

Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J. 2007;30:508–16. https://doi.org/10.1183/09031936.00002607.

Article  PubMed  Google Scholar 

Gupta N, Bleesing JH, McCormack FX. Successful response to treatment with Sirolimus in Pulmonary Sarcoidosis. Am J Respir Crit Care Med. 2020;202:E119–20. https://doi.org/10.1164/RCCM.202004-0914IM.

Article  PubMed  Google Scholar 

Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: A comprehensive review and update for the dermatologist: Part I. Cutaneous disease J Am Acad Dermatol. 2012a;66:699.e1–699.e18.

PubMed  Google Scholar 

Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: A comprehensive review and update for the dermatologist: Part II. Extracutaneous disease J Am Acad Dermatol. 2012b;66:719.e1–719.e10.

PubMed  Google Scholar 

Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. cutaneous disease. J Am Acad Dermatol. 2012c;66:699.e1-699.e18. https://doi.org/10.1016/J.JAAD.2011.11.965

Hiraki T, Hatanaka M, Arimura A, et al. Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence. J Cutan Pathol. 2020;47:154–60. https://doi.org/10.1111/CUP.13569.

Article  PubMed  Google Scholar 

Imadojemu S, Wanat KA, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: Sarcoidosis: a clinician’s guide. Elsevier; 2018. pp. 127–44. https://doi.org/10.1016/B978-0-323-54429-0.00011-2.

Jespersen H, Bjursten S, Ny L, Levin M. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. Lancet Oncol. 2018;19:e327. https://doi.org/10.1016/S1470-2045(18)30252-3.

Article  PubMed  Google Scholar 

Jorizzo JL, Koufman JA, Thompson JN, et al. Sarcoidosis of the upper respiratory tract in patients with nasal rim lesions: a pilot study. J Am Acad Dermatol. 1990;22:439–43. https://doi.org/10.1016/0190-9622(90)70061-l.

Article  PubMed  Google Scholar 

Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:119–27.

PubMed  Google Scholar 

Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. WASOG Sarcoidosis Organ Assessment Instrument Investigators*; 2014.

Google Scholar 

Kelleher KJ, Russell J, Killeen OG, Leahy TR. Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus. BMJ Case Rep. 2020;13. https://doi.org/10.1136/BCR-2020-235372.

Mañá J, Marcoval J, Graells J, Salazar A, Peyrí J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol. 1997;133:882. https://doi.org/10.1001/ARCHDERM.1997.03890430098013.

Manansala M, Sami F, Arora S, Manadan AM. Reasons for hospitalization and all-cause mortality for adults with Sarcoidosis. Am J Med open. 2023;9:100037. https://doi.org/10.1016/J.AJMO.2023.100037.

Article  PubMed  PubMed Central  Google Scholar 

Marinescu DC, Raghu G, Remy-Jardin M, et al. Integration and application of clinical practice guidelines for the diagnosis of idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Chest. 2022;162:614–29. https://doi.org/10.1016/J.CHEST.2022.06.013.

Article  PubMed  Google Scholar 

McDermott KW, Roemer M. Most frequent principal diagnoses for Inpatient stays in U.S. hospitals, 2018. Healthcare cost and utilization project (HCUP) statistical briefs. Rockville, MD: Agency for healthcare research and Quality (US); 2021.

Mitchell B, Chong C, Lim WK. Medication adherence 1 month after hospital discharge in medical inpatients. Intern Med J. 2016;46:185–92. https://doi.org/10.1111/IMJ.12965.

Article  PubMed  Google Scholar 

Nakamura S, Hashimoto Y, Nishi K, et al. High rate of cardiac sarcoidosis presenting with cutaneous plaque type sarcoidosis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography: a case series. J Med Case Rep. 2014;8. https://doi.org/10.1186/1752-1947-8-17.

Noe MH, Rosenbach M. Cutaneous sarcoidosis. Curr Opin Pulm Med. 2017;23:482–6.

Article  PubMed  Google Scholar 

Ohira H, Sato T, Manabe O, et al. Underdiagnosis of cardiac sarcoidosis by ECG and echocardiography in cases of extracardiac sarcoidosis. ERJ Open Res. 2022;8. https://doi.org/10.1183/23120541.00516-2021.

Park SK, Hwang PH, Yun SK, et al. Tumor necrosis factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with juvenile rheumatoid arthritis: a Case Report and Review of the literature. Ann Dermatol. 2017;29:74–8. https://doi.org/10.5021/AD.2017.29.1.74.

Article  PubMed  PubMed Central